{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T04:07:33Z","timestamp":1795147653276,"version":"4.10.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100011541","name":"U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA214608-02"],"award-info":[{"award-number":["R01 CA214608-02"]}],"id":[{"id":"10.13039\/100011541","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U19AI109740"],"award-info":[{"award-number":["U19AI109740"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dana-Farber Cancer Institute Medicinal Chemistry Core"},{"name":"Quadrangle Fund for the Advancement and Seeding of Translational Research at Harvard Medical School"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Targeted protein degradation is a promising drug development paradigm. Here we leverage this strategy to develop a new class of small molecule antivirals that induce proteasomal degradation of viral proteins. Telaprevir, a reversible-covalent inhibitor that binds to the hepatitis C virus (HCV) protease active site is conjugated to ligands that recruit the CRL4\n                    <jats:sup>CRBN<\/jats:sup>\n                    ligase complex, yielding compounds that can both inhibit and induce the degradation of the HCV NS3\/4A protease. An optimized degrader, DGY-08-097, potently inhibits HCV in a cellular infection model, and we demonstrate that protein degradation contributes to its antiviral activity. Finally, we show that this new class of antiviral agents can overcome viral variants that confer resistance to traditional enzymatic inhibitors such as telaprevir. Overall, our work provides proof-of-concept that targeted protein degradation may provide a new paradigm for the development of antivirals with superior resistance profiles.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-11429-w","type":"journal-article","created":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T06:02:43Z","timestamp":1564639363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":234,"title":["Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0682-3054","authenticated-orcid":false,"given":"M\u00e9lissanne","family":"de Wispelaere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangyan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-5106","authenticated-orcid":false,"given":"Katherine A.","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tinghu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Eleuteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingting C.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Kalabathula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-0071","authenticated-orcid":false,"given":"Rados\u0142aw P.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7337-6306","authenticated-orcid":false,"given":"Eric S.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7403","authenticated-orcid":false,"given":"Nathanael S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla L.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,1]]},"reference":[{"key":"11429_CR1","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky, J. M., Feld, J. J., Zeuzem, S. & Hoofnagle, J. H. From non-A, non-B hepatitis to hepatitis C virus cure. J. Hepatol. 62, S87\u2013S99 (2015).","journal-title":"J. Hepatol."},{"key":"11429_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chembiol.2017.05.024","volume":"24","author":"PM Cromm","year":"2017","unstructured":"Cromm, P. M. & Crews, C. M. Targeted protein degradation: from chemical biology to drug discovery. Cell Chem. Biol. 24, 1181\u20131190 (2017).","journal-title":"Cell Chem. Biol."},{"key":"11429_CR3","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1021\/ja039025z","volume":"126","author":"JS Schneekloth","year":"2004","unstructured":"Schneekloth, J. S. et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. J. Am. Chem. Soc. 126, 3748\u20133754 (2004).","journal-title":"J. Am. Chem. Soc."},{"key":"11429_CR4","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611\u2013617 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"11429_CR5","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1002\/anie.201507634","volume":"55","author":"AC Lai","year":"2016","unstructured":"Lai, A. C. et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int Ed. Engl. 55, 807\u2013810 (2016).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"11429_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nchembio.2538","volume":"14","author":"CM Olson","year":"2018","unstructured":"Olson, C. M. et al. Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nat. Chem. Biol. 14, 163\u2013170 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"11429_CR7","doi-asserted-by":"publisher","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","volume":"115","author":"A Zorba","year":"2018","unstructured":"Zorba, A. et al. Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc. Natl Acad. Sci. USA 115, E7285\u2013E7292 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11429_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.molcel.2017.06.004","volume":"67","author":"GE Winter","year":"2017","unstructured":"Winter, G. E. et al. BET bromodomain proteins function as master transcription elongation factors independent of CDK9 recruitment. Mol. Cell 67, 5\u201318 e19 (2017).","journal-title":"Mol. Cell"},{"key":"11429_CR9","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41589-018-0010-y","volume":"14","author":"LN Gechijian","year":"2018","unstructured":"Gechijian, L. N. et al. Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat. Chem. Biol. 14, 405\u2013412 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"11429_CR10","doi-asserted-by":"publisher","first-page":"5738","DOI":"10.1002\/anie.201611281","volume":"56","author":"D Remillard","year":"2017","unstructured":"Remillard, D. et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angew. Chem. Int Ed. Engl. 56, 5738\u20135743 (2017).","journal-title":"Angew. Chem. Int Ed. Engl."},{"key":"11429_CR11","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","volume":"57","author":"AD Buhimschi","year":"2018","unstructured":"Buhimschi, A. D. et al. Targeting the C481S ibrutinib-resistance mutation in Bruton's tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57, 3564\u20133575 (2018).","journal-title":"Biochemistry"},{"key":"11429_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.chembiol.2017.09.009","volume":"25","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. The advantages of targeted protein degradation over inhibition: an RTK case study. Cell Chem. Biol. 25, 67\u201377 e63 (2018).","journal-title":"Cell Chem. Biol."},{"key":"11429_CR13","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1073\/pnas.1521738113","volume":"113","author":"K Raina","year":"2016","unstructured":"Raina, K. et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 113, 7124\u20137129 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11429_CR14","volume-title":"Global Hepatitis Report 2017.","author":"WH Organization","year":"2017","unstructured":"Organization, W. H. Global Hepatitis Report 2017. (World Health Organization, Geneva, Switzerland, 2017)."},{"key":"11429_CR15","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2893.2011.01451.x","volume":"18","author":"K Morikawa","year":"2011","unstructured":"Morikawa, K. et al. Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J. Viral Hepat. 18, 305\u2013315 (2011).","journal-title":"J. Viral Hepat."},{"key":"11429_CR16","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1073\/pnas.0408824102","volume":"102","author":"K Li","year":"2005","unstructured":"Li, K. et al. Immune evasion by hepatitis C virus NS3\/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad. Sci. USA 102, 2992\u20132997 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"11429_CR17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/nature04193","volume":"437","author":"E Meylan","year":"2005","unstructured":"Meylan, E. et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437, 1167\u20131172 (2005).","journal-title":"Nature"},{"key":"11429_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1128\/AAC.50.3.899-909.2006","volume":"50","author":"RB Perni","year":"2006","unstructured":"Perni, R. B. et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 50, 899\u2013909 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"11429_CR19","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767\u20131777 (2007).","journal-title":"Gastroenterology"},{"key":"11429_CR20","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"C Hezode","year":"2009","unstructured":"Hezode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med 360, 1839\u20131850 (2009).","journal-title":"N. Engl. J. Med"},{"key":"11429_CR21","doi-asserted-by":"publisher","first-page":"17508","DOI":"10.1074\/jbc.M313020200","volume":"279","author":"C Lin","year":"2004","unstructured":"Lin, C. et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J. Biol. Chem. 279, 17508\u201317514 (2004).","journal-title":"J. Biol. Chem."},{"key":"11429_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coviro.2014.04.008","volume":"8","author":"TL Kieffer","year":"2014","unstructured":"Kieffer, T. L. & George, S. Resistance to hepatitis C virus protease inhibitors. Curr. Opin. Virol. 8, 16\u201321 (2014).","journal-title":"Curr. Opin. Virol."},{"key":"11429_CR23","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.antiviral.2013.04.018","volume":"99","author":"N Palanisamy","year":"2013","unstructured":"Palanisamy, N. et al. Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a. Antivir. Res 99, 12\u201317 (2013).","journal-title":"Antivir. Res"},{"key":"11429_CR24","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/591141","volume":"198","author":"DJ Bartels","year":"2008","unstructured":"Bartels, D. J. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800\u2013807 (2008).","journal-title":"J. Infect. Dis."},{"key":"11429_CR25","doi-asserted-by":"publisher","first-page":"e1002832","DOI":"10.1371\/journal.ppat.1002832","volume":"8","author":"KP Romano","year":"2012","unstructured":"Romano, K. P. et al. The molecular basis of drug resistance against hepatitis C virus NS3\/4A protease inhibitors. PLoS Pathog. 8, e1002832 (2012).","journal-title":"PLoS Pathog."},{"issue":"7","key":"11429_CR26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","volume":"14","author":"Rados\u0142aw P. Nowak","year":"2018","unstructured":"Nowak, R. P. et al. Plasticity in binding confers selectivity in ligand-induced protein degradation. Nat. Chem Biol. https:\/\/doi.org\/10.1038\/s41589-018-0055-y (2018).","journal-title":"Nature Chemical Biology"},{"key":"11429_CR27","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona, A. et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26, 2326\u20132335 (2012).","journal-title":"Leukemia"},{"key":"11429_CR28","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/cmdc.201800271","volume":"13","author":"GM Burslem","year":"2018","unstructured":"Burslem, G. M. et al. Efficient synthesis of immunomodulatory drug analogues enables exploration of structure-degradation relationships. ChemMedChem 13, 1508\u20131512 (2018).","journal-title":"ChemMedChem"},{"key":"11429_CR29","doi-asserted-by":"publisher","unstructured":"Schultz, B., Yang, H. & Delaney, W. E. t. Biochemical evaluation of HCV NS3 protease inhibitors. Curr. Protoc. Pharmacol. 13B\u201317. https:\/\/doi.org\/10.1002\/0471141755.ph13b07s54 (2011).","DOI":"10.1002\/0471141755.ph13b07s54"},{"key":"11429_CR30","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1126\/science.1160489","volume":"322","author":"HC Yen","year":"2008","unstructured":"Yen, H. C., Xu, Q., Chou, D. M., Zhao, Z. & Elledge, S. J. Global protein stability profiling in mammalian cells. Science 322, 918\u2013923 (2008).","journal-title":"Science"},{"key":"11429_CR31","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature07884","volume":"458","author":"TA Soucy","year":"2009","unstructured":"Soucy, T. A. et al. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458, 732\u2013736 (2009).","journal-title":"Nature"},{"key":"11429_CR32","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1128\/AAC.00863-07","volume":"52","author":"Y Zhou","year":"2008","unstructured":"Zhou, Y. et al. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52, 110\u2013120 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"11429_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-1-r16","volume":"9","author":"C Welsch","year":"2008","unstructured":"Welsch, C. et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biol. 9, R16 (2008).","journal-title":"Genome Biol."},{"key":"11429_CR34","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1128\/AAC.05184-11","volume":"56","author":"C Welsch","year":"2012","unstructured":"Welsch, C. et al. Ketoamide resistance and hepatitis C virus fitness in val55 variants of the NS3 serine protease. Antimicrob. Agents Chemother. 56, 1907\u20131915 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"11429_CR35","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito, T. et al. Identification of a primary target of thalidomide teratogenicity. Science 327, 1345\u20131350 (2010).","journal-title":"Science"},{"issue":"6336","key":"11429_CR36","doi-asserted-by":"publisher","first-page":"eaal3755","DOI":"10.1126\/science.aal3755","volume":"356","author":"Ting Han","year":"2017","unstructured":"Han, T. et al. Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15. Science 356, https:\/\/doi.org\/10.1126\/science.aal3755 (2017).","journal-title":"Science"},{"key":"11429_CR37","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nchembio.2363","volume":"13","author":"T Uehara","year":"2017","unstructured":"Uehara, T. et al. Selective degradation of splicing factor CAPERalpha by anticancer sulfonamides. Nat. Chem. Biol. 13, 675\u2013680 (2017).","journal-title":"Nat. Chem. Biol."},{"key":"11429_CR38","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1126\/science.1114016","volume":"309","author":"BD Lindenbach","year":"2005","unstructured":"Lindenbach, B. D. et al. Complete replication of hepatitis C virus in cell culture. Science 309, 623\u2013626 (2005).","journal-title":"Science"},{"key":"11429_CR39","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1053\/j.gastro.2003.09.023","volume":"125","author":"T Kato","year":"2003","unstructured":"Kato, T. et al. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125, 1808\u20131817 (2003).","journal-title":"Gastroenterology"},{"key":"11429_CR40","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"11429_CR41","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","volume":"25","author":"HT Huang","year":"2018","unstructured":"Huang, H. T. et al. A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader. Cell Chem. Biol. 25, 88\u201399 e86 (2018).","journal-title":"Cell Chem. Biol."},{"key":"11429_CR42","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita, T. et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11, 791\u2013796 (2005).","journal-title":"Nat. Med."},{"key":"11429_CR43","doi-asserted-by":"publisher","first-page":"13168","DOI":"10.1128\/JVI.01362-07","volume":"81","author":"A Kaul","year":"2007","unstructured":"Kaul, A., Woerz, I., Meuleman, P., Leroux-Roels, G. & Bartenschlager, R. Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant. J. Virol. 81, 13168\u201313179 (2007).","journal-title":"J. Virol."},{"key":"11429_CR44","doi-asserted-by":"publisher","first-page":"8379","DOI":"10.1128\/JVI.00891-09","volume":"83","author":"T Phan","year":"2009","unstructured":"Phan, T., Beran, R. K., Peters, C., Lorenz, I. C. & Lindenbach, B. D. Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J. Virol. 83, 8379\u20138395 (2009).","journal-title":"J. Virol."},{"key":"11429_CR45","doi-asserted-by":"publisher","first-page":"7426","DOI":"10.1128\/AAC.01953-15","volume":"59","author":"SB Jensen","year":"2015","unstructured":"Jensen, S. B. et al. Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob. Agents Chemother. 59, 7426\u20137436 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"11429_CR46","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/hep.23192","volume":"50","author":"S Susser","year":"2009","unstructured":"Susser, S. et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50, 1709\u20131718 (2009).","journal-title":"Hepatology"},{"key":"11429_CR47","doi-asserted-by":"publisher","first-page":"e1002627","DOI":"10.1371\/journal.ppat.1002627","volume":"8","author":"AG Schmidt","year":"2012","unstructured":"Schmidt, A. G., Lee, K., Yang, P. L. & Harrison, S. C. Small-molecule inhibitors of dengue-virus entry. PLoS Pathog. 8, e1002627 (2012).","journal-title":"PLoS Pathog."},{"key":"11429_CR48","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1021\/jm030191r","volume":"46","author":"J Seidler","year":"2003","unstructured":"Seidler, J., McGovern, S. L., Doman, T. N. & Shoichet, B. K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J. Med. Chem. 46, 4477\u20134486 (2003).","journal-title":"J. Med. Chem."},{"issue":"3","key":"11429_CR49","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1021\/acsinfecdis.8b00322","volume":"5","author":"Pi-Chun Li","year":"2019","unstructured":"Li, P. C. et al. Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in vivo. ACS Infect. Dis. https:\/\/doi.org\/10.1021\/acsinfecdis.8b00322 (2019).","journal-title":"ACS Infectious Diseases"},{"key":"11429_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2006-7-10-r100","volume":"7","author":"AE Carpenter","year":"2006","unstructured":"Carpenter, A. E. et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 7, R100 (2006).","journal-title":"Genome Biol."},{"key":"11429_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15398","volume":"8","author":"J An","year":"2017","unstructured":"An, J. et al. pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4(CRBN) ubiquitin ligase. Nat. Commun. 8, 15398 (2017).","journal-title":"Nat. Commun."},{"key":"11429_CR52","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.1021\/ac502040v","volume":"86","author":"GC McAlister","year":"2014","unstructured":"McAlister, G. C. et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86, 7150\u20137158 (2014).","journal-title":"Anal. Chem."},{"key":"11429_CR53","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res"},{"key":"11429_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/978-1-59745-394-3_24","volume":"510","author":"BD Lindenbach","year":"2009","unstructured":"Lindenbach, B. D. Measuring HCV infectivity produced in cell culture and in vivo. Methods Mol. Biol. 510, 329\u2013336 (2009).","journal-title":"Methods Mol. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11429-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11429-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:40:29Z","timestamp":1671219629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11429-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,1]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11429"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11429-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,1]]},"assertion":[{"value":"2 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.S.G. is an equity holder and scientific advisor for Syros, Gatekeeper, Soltego, C4, B2S, Petra and Aduro companies. N.S.G., G.D., P.L.Y., M.d.W. are inventors on a patent covering the compounds described in this paper. E.S.F is an equity holder and scientific advisor for C4 Therapeutics and Civetta Therapeutics and is a consultant to Novartis, AbbVie, Pfizer, and Deerfield. E.S.F received research funding from Novartis and Astellas not related to this work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3468"}}